

**Table 2.2**  
**Verified Outcomes (Annualized Percentages) by Age at Enrollment for Hormone Therapy Participants**

Data as of: September 30, 2015; Events through September 30, 2015

Outcomes	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
<b>Number randomized</b>	27347	3420	5413	12360	6154
<b>Mean follow-up (months)</b>	171.4	184.5	182.3	172.9	151.3
<b>Cardiovascular</b>					
CHD <sup>1</sup>	2154 (0.55%)	111 (0.21%)	240 (0.29%)	1000 (0.56%)	803 (1.03%)
CHD death <sup>2</sup>	782 (0.20%)	23 (0.04%)	59 (0.07%)	312 (0.18%)	388 (0.50%)
Total MI <sup>3</sup>	1615 (0.41%)	93 (0.18%)	204 (0.25%)	776 (0.44%)	542 (0.70%)
Clinical MI	1585 (0.41%)	92 (0.17%)	202 (0.25%)	761 (0.43%)	530 (0.68%)
Angina <sup>4</sup>	1086 (0.49%)	52 (0.18%)	139 (0.31%)	526 (0.53%)	369 (0.77%)
CABG/PTCA	2073 (0.53%)	130 (0.25%)	312 (0.38%)	1061 (0.60%)	570 (0.73%)
Carotid artery disease	388 (0.10%)	10 (0.02%)	56 (0.07%)	214 (0.12%)	108 (0.14%)
Congestive heart failure, WHI <sup>4</sup>	806 (0.36%)	41 (0.14%)	75 (0.17%)	333 (0.34%)	357 (0.75%)
Heart failure, UNC <sup>5</sup>	1678 (0.43%)	66 (0.13%)	146 (0.18%)	745 (0.42%)	721 (0.93%)
Stroke	1631 (0.42%)	73 (0.14%)	158 (0.19%)	766 (0.43%)	634 (0.82%)
Non-disabling stroke <sup>6</sup>	873 (0.22%)	54 (0.10%)	106 (0.13%)	405 (0.23%)	308 (0.40%)
Fatal/disabling stroke <sup>6</sup>	694 (0.18%)	16 (0.03%)	45 (0.05%)	329 (0.18%)	304 (0.39%)
Unknown status from stroke <sup>6</sup>	64 (0.02%)	3 (0.01%)	7 (0.01%)	32 (0.02%)	22 (0.03%)
PVD	419 (0.11%)	22 (0.04%)	51 (0.06%)	219 (0.12%)	127 (0.16%)
DVT	839 (0.21%)	57 (0.11%)	133 (0.16%)	400 (0.22%)	249 (0.32%)
Pulmonary embolism	659 (0.17%)	44 (0.08%)	103 (0.13%)	324 (0.18%)	188 (0.24%)
DVT/PE	1194 (0.31%)	76 (0.14%)	182 (0.22%)	589 (0.33%)	347 (0.45%)
Coronary disease <sup>7</sup>	4612 (1.18%)	256 (0.49%)	573 (0.70%)	2161 (1.21%)	1622 (2.09%)
Aortic aneurysm <sup>8</sup>	31 (0.03%)	0 (0.00%)	4 (0.02%)	21 (0.04%)	6 (0.03%)
Atrial fibrillation <sup>8</sup>	771 (0.68%)	44 (0.30%)	106 (0.45%)	425 (0.83%)	196 (0.86%)
Valvular heart disease <sup>8</sup>	200 (0.18%)	9 (0.06%)	26 (0.11%)	114 (0.22%)	51 (0.22%)
<b>Total cardiovascular disease<sup>9</sup></b>	<b>7051 (1.81%)</b>	<b>405 (0.77%)</b>	<b>891 (1.08%)</b>	<b>3354 (1.88%)</b>	<b>2401 (3.09%)</b>
<b>Cancer</b>					
Breast cancer	1728 (0.44%)	198 (0.38%)	360 (0.44%)	809 (0.45%)	361 (0.47%)
Invasive breast cancer	1422 (0.36%)	152 (0.29%)	299 (0.36%)	654 (0.37%)	317 (0.41%)
Non-invasive breast cancer	333 (0.09%)	47 (0.09%)	67 (0.08%)	170 (0.10%)	49 (0.06%)
Ovarian cancer	157 (0.04%)	12 (0.02%)	31 (0.04%)	82 (0.05%)	32 (0.04%)
Endometrial cancer <sup>10</sup>	214 (0.05%)	34 (0.06%)	48 (0.06%)	93 (0.05%)	39 (0.05%)
Colorectal cancer	576 (0.15%)	42 (0.08%)	75 (0.09%)	291 (0.16%)	168 (0.22%)
Other cancer <sup>11</sup>	2634 (0.67%)	205 (0.39%)	415 (0.50%)	1301 (0.73%)	713 (0.92%)
<b>Total cancer</b>	<b>4962 (1.27%)</b>	<b>463 (0.88%)</b>	<b>878 (1.07%)</b>	<b>2390 (1.34%)</b>	<b>1231 (1.59%)</b>
<b>Fractures</b>					
Hip fracture	1070 (0.27%)	26 (0.05%)	78 (0.09%)	445 (0.25%)	521 (0.67%)
<b>Deaths</b>					
Cardiovascular deaths	1653 (0.42%)	50 (0.10%)	113 (0.14%)	659 (0.37%)	831 (1.07%)
Cancer deaths	1775 (0.45%)	106 (0.20%)	247 (0.30%)	870 (0.49%)	552 (0.71%)
Other known cause	1500 (0.38%)	54 (0.10%)	127 (0.15%)	658 (0.37%)	661 (0.85%)
Unknown cause	44 (0.01%)	3 (0.01%)	8 (0.01%)	18 (0.01%)	15 (0.02%)
Not yet adjudicated	260 (0.07%)	10 (0.02%)	19 (0.02%)	116 (0.07%)	115 (0.15%)
<b>Total death</b>	<b>5232 (1.34%)</b>	<b>223 (0.42%)</b>	<b>514 (0.62%)</b>	<b>2321 (1.30%)</b>	<b>2174 (2.80%)</b>
<b>Death plus post-WHI deaths<sup>12</sup></b>	<b>7427 (1.66%)</b>	<b>308 (0.50%)</b>	<b>670 (0.71%)</b>	<b>3196 (1.58%)</b>	<b>3253 (3.62%)</b>

<sup>1</sup> "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2015.

<sup>2</sup> "CHD death" includes definite and possible CHD death.

<sup>3</sup> "Total MI" includes clinical MI and evolving Q-wave MI; Q-wave MI is not collected in the WHI Extension Studies 2005-2015.

<sup>4</sup> Angina and CHF are not verified outcomes during the WHI Extension Studies 2005-2015. Reported statistics represent experience during the original program.

<sup>5</sup> Definite or possible decompensated heart failure adjudicated by UNC.

<sup>6</sup> Non-disabling stroke includes Glasgow scales 1 and 2; fatal/disabling includes Glasgow scales 3-5 and death within 1 month of stroke; and unknown status includes Glasgow scale 6 and status not yet known.

<sup>7</sup> "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina and CHF are not collected in the WHI Extension Studies 2005-2015.

<sup>8</sup> Aortic aneurysm, atrial fibrillation and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2015.

<sup>9</sup> Total CVD does not include aortic aneurysm, atrial fibrillation or valvular heart disease.

<sup>10</sup> Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

<sup>11</sup> Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

<sup>12</sup> Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.